Key facts
- This page summarizes Frazier Life Sciences X, L.P.'s Form 4 filing for MBX Biosciences, Inc. (MBX).
- 4 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 17 Sep 2024, 20:11.
Frazier Life Sciences X, L.P. - 16 Sep 2024 Form 4 Insider Report for MBX Biosciences, Inc. (MBX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- MBX
- Reported as of
- 16 Sep 2024
- Net transaction value
- +$10,000,000
- SEC form
- 4
- Accepted by SEC
- 17 Sep 2024, 20:11:37 UTC
- Prior SEC filing
- 12 Sep 2024
- Next SEC filing
- 17 Sep 2025
- Source filing
- View source filing
- Reporting owner signature
- Frazier Life Sciences X, L.P., By: FHMLS X, L.P., its general partner, By: FHMLS X, L.L.C., its general partner, By: /s/ Steve R. Bailey, Chief Financial Officer
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Frazier Life Sciences X, L.P. filed Form 4 for MBX Biosciences, Inc. (MBX) on 17 Sep 2024.
Change
- Previous filing in this sequence was filed on 12 Sep 2024.
- Current net transaction value: +$10,000,000.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MBX
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +3,927,774
- Change %
- Price
- Shares after
- 3,927,774
- Date
- 16 Sep 2024
- Ownership
- Direct
- Footnotes
- F1, F2
MBX
transaction
Common Stock
Purchase
- Transaction value
- $10,000,000
- Shares
- +625,000
- Change %
- +16%
- Price
- $16.00
- Shares after
- 4,552,774
- Date
- 16 Sep 2024
- Ownership
- Direct
- Footnotes
- F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MBX
transaction
Derivative
Series A Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -18,922,852
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,574,005
- Exercise price
- Footnotes
- F1, F2
MBX
transaction
Derivative
Series B Convertible Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -28,297,265
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 16 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,353,769
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.
Footnote F2
These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. Mr. Heron and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Footnote F3
Reflects shares purchased in the Issuer's initial public offering.